CN100569240C - The pharmaceutical applications of Hesperidin and/or naringin - Google Patents
The pharmaceutical applications of Hesperidin and/or naringin Download PDFInfo
- Publication number
- CN100569240C CN100569240C CNB2004100426585A CN200410042658A CN100569240C CN 100569240 C CN100569240 C CN 100569240C CN B2004100426585 A CNB2004100426585 A CN B2004100426585A CN 200410042658 A CN200410042658 A CN 200410042658A CN 100569240 C CN100569240 C CN 100569240C
- Authority
- CN
- China
- Prior art keywords
- hesperidin
- naringin
- compositions
- purposes
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 title claims abstract description 49
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 title claims abstract description 49
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 title claims abstract description 49
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 title claims abstract description 49
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 title claims abstract description 49
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 title claims abstract description 49
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 title claims abstract description 49
- 229940025878 hesperidin Drugs 0.000 title claims abstract description 49
- 229930019673 naringin Natural products 0.000 title claims abstract description 49
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 title claims abstract description 49
- 229940052490 naringin Drugs 0.000 title claims abstract description 49
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 15
- 230000030135 gastric motility Effects 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 208000022531 anorexia Diseases 0.000 claims abstract description 4
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 4
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 4
- 206010016766 flatulence Diseases 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 19
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 230000030136 gastric emptying Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 4
- 229960001253 domperidone Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 4
- 229960002362 neostigmine Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 241000207199 Citrus Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241000555268 Dendroides Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000009253 Xiexin decoction Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses Hesperidin and/or naringin and have the purposes that promotes the gastric motility drugs with function in preparation.Hesperidin and/or naringin are in the purposes of preparation treatment flatulence, dyspepsia, infantile anorexia medicine.
Description
Technical field
The present invention relates to Hesperidin and/or naringin promote the gastric motility drugs with function in preparation purposes.
Background technology
In recent years, human learn and the understanding of dysfunction has had significant progress gastric motility is sick, power is as one of important physiological function of human stomach, obtained that medical circle is increasing to be paid close attention to and research.Gastric dynamic dysfunction usually can cause diseases such as flatulence, dyspepsia or infantile anorexia.The chemical drugs of stomach motility enhancing has had many, as motilium, cisapride, erythromycin etc., but acts on limitedly, and because of costing an arm and a leg and problem such as side effect is more, clinical practice is subjected to certain restriction.
Chinese medicine has many compound recipes to have the effect of stomach motility enhancing, and as Sini San, banxia xiexin decoction, Ginseng Decoction, Xiao Jianzhong Tang etc., but Chinese medicine monomer research is less.Hesperidin and naringin are the Flavonoid substances that extensively is present in Fructus Citri grandis, Citrus, orange, Fructus Aurantii Immaturus, the Fructus Aurantii, be used as bitters, stimulant, also had a curative effect of cholesterol reducing and treatment acute/chronic bronchitis, but, do not report that still Hesperidin and naringin have the application that promotes the gastric motility effect.
The structure of Hesperidin is:
Molecular formula: C
28H
34O
15, thin dendroid acicular crystal (pH6～7 precipitation gained).M.p.258～262 ℃, [α]
D 20-76 ° (c 2, pyridine).Slightly be slightly soluble in methanol and hot glacial acetic acid, be dissolved in acetone, benzene and chloroform hardly, and be soluble in diluted alkaline and pyridine.
The structure of naringin is:
Molecular formula: C
27H
32O
14, being dried to weight at 110 ℃ is two water things, m.p.171 ℃.[α]
D 19-82 ° (ethanol).1 gram is dissolved in 1000ml water, is dissolved in acetone, ethanol, hot acetic acid and hot water, is insoluble to ether, hexane and chloroform.
Summary of the invention
The object of the present invention is to provide Hesperidin and/or naringin to promote the purposes of gastric motility medicine in preparation.
The inventor suppresses mice gastric emptying and neostigmine at atropine, dopamine and causes the mouse small intestine carbon powder and advance in two kinds of experimental models that Hesperidin, naringin and compositions have the effect that promotes digestive tract power among the unexpected the present invention of discovery.Particularly, Hesperidin, naringin and compositions are better than motilium to the influence that dopamine suppresses the gastric emptying motion.
Because Hesperidin and/or naringin have the effect that promotes gastric motility, so they can prepare the medicine for the treatment of flatulence, dyspepsia or infantile anorexia disease.
Hesperidin among the present invention and/or naringin not only pharmacological action are strong, the more important thing is that toxicity is little, the LD of Hesperidin
50Value is the LD of 3.83 ± 0.480g/kg, naringin
50Value is the LD of 3.51 ± 0.382g/kg, compositions
50Value is 4.10 ± 0.410g/kg.Far below the Western medicine motilium, has good prospect in medicine in toxicity.
Hesperidin of the present invention and/or naringin can be to extract Hesperidin and/or naringin crude product or Hesperidin and/or the pure product of naringin monomer of obtaining from the various medical materials that contain Hesperidin and/or naringin such as Fructus Aurantii Immaturus, Fructus Aurantii, Citrus, Fructus Citri Limoniae, grapefruit, dried tangerine peel, orange etc.Extracting method is the medical material fine powder, use ethanol extraction, extracting solution reclaims ethanol to there not being the alcohol flavor, add distilled water, use petroleum ether, ethyl acetate and n-butanol extraction successively, the n-butanol extraction position is behind concentrate drying, last D101 type macroporous resin column, water, 25% ethanol, 50% ethanol and 95% ethanol elution successively, 50% ethanol elution position behind concentrate drying the mixing total glycosides of Hesperidin and naringin, separate Hesperidin and the pure product of naringin monomer of obtaining through silica gel column chromatography.
Hesperidin of the present invention and/or naringin also can be according to Rosenmund (Rosenmund, Ber., 61,2608 (1958)) and Zemlen, and the method that Bognar (Ber., 75,648 (1942)) describes or other chemical methodes are synthesized and obtained.
Hesperidin among the present invention and/or naringin can adopt the conventional method of this area to be prepared into various dosage forms, as tablet, pill, capsule, granule, injection etc. with pharmaceutically acceptable excipient.The preferred dosage form that contains the pharmaceutical composition of Hesperidin of the present invention and naringin is an oral formulations.Dosage be 20-500mg/ people/time, every day 1-3 time.
Experimental example 1. animal acute toxicity tests
(1) oral administration
Healthy male mice, body weight 18-25 gram is used Hesperidin, naringin or its compositions (Hesperidin and naringin ratio are 1: 1) to be made into aqueous solution respectively and is irritated stomach 5.0g/kg, in a continuous week, does not see dead mouse.
(2) drug administration by injection
Healthy male mice, body weight 18-25 gram is used Hesperidin, naringin or its compositions (Hesperidin and naringin ratio are 1: 1) to be made into aqueous solution respectively and is carried out lumbar injection, in a continuous week, observes the dead mouse situation.The LD of Hesperidin
50Value is the LD of 3.83 ± 0.480g/kg, naringin
50Value is the LD of 3.51 ± 0.382g/kg, compositions
50Value is 4.10 ± 0.410g/kg.
The influence of 2. pairs of mice gastric emptyings of experimental example
Adopt atropine, dopamine inhibition mice gastric emptying and neostigmine to cause the mouse small intestine carbon powder and advance two kinds of experimental models, Hesperidin, naringin and compositions promote the effect of digestive tract power among checking the present invention.
The experimental drug thing is respectively among the present invention gained Hesperidin, naringin and compositions (Hesperidin and naringin ratio are 1: 1) among the embodiment, faces with preceding and prepares with 0.5%CMC-Na; Reference substance is motilium (an Xi'an Janssen Pharmaceutica lot number 010203), faces with preceding and prepares with distilled water.
2.1 atropine, dopamine are suppressed the influence of mice gastric emptying
Hesperidin, naringin and compositions and blank group relatively have significant difference (P＜0.001) among the present invention.The results are shown in Table 1 and table 2.
Table 1 Hesperidin, naringin and compositions suppress the influence of gastric emptying motion to atropine
Table 2 Hesperidin, naringin and compositions suppress the influence of gastric emptying motion to dopamine
2.2 neostigmine is caused the propulsive influence of mouse small intestine carbon powder
Hesperidin, naringin and compositions and blank group relatively have significant difference (P＜0.01) among the present invention, the results are shown in Table 3.
Table 3 Hesperidin, naringin and compositions cause mice gastric emptying and the propulsive influence of small intestinal carbon powder to neostigmine
Various details embodiment, but content of the present invention is not limited to this fully.
The specific embodiment
Embodiment 1:
Fructus Aurantii Immaturus fine powder 600g, 3 times (crude drug: the weight of solvent ratio is 1: 8 with 70% ethanol extraction; 1: 6; 1: 6), merge extractive liquid, reclaims ethanol to there not being the alcohol flavor, adds distilled water to 600ml, and water liquid is used petroleum ether, ethyl acetate and n-butanol extraction successively, each 300ml.The n-butanol extraction position gets 82g behind concentrate drying, last D101 type macroporous resin column, water, 25% ethanol, 50% ethanol and 95% ethanol elution successively, 50% ethanol elution position through behind the concentrate drying Hesperidin more than 20% and the mixing total glycosides (47g) of naringin, obtain Hesperidin (95% through the silica gel column chromatography separation, 20g) and naringin (95%, 15g) pure product.Through respectively with IR, the UV of Hesperidin and naringin standard substance, NMR, m.p. and TLC relatively, determined the chemical constitution of above two pure product.
Embodiment 2:
Hesperidin (2g) and naringin (18g) are fully mixed with 1: 9 ratio, stir, grind the compositions (20g) of Hesperidin and naringin.
Embodiment 3:
Hesperidin (10g) and naringin (10g) are fully mixed with 1: 1 ratio, stir, grind the compositions (20g) of Hesperidin and naringin.
Embodiment 4:
Hesperidin (18g) and naringin (2g) are fully mixed with 9: 1 ratios, stir, grind the compositions (20g) of Hesperidin and naringin.
Claims (5)
1. the compositions of being made up of Hesperidin and naringin is preparing the purposes that promotes the gastric motility medicine, and it is characterized in that: the mass percent of Hesperidin and naringin is 1: 1.
2. purposes according to claim 1, wherein said medicine are the medicines of treatment flatulence, dyspepsia or infantile anorexia.
3. according to the described purposes of claim 3, wherein said Hesperidin and naringin extract acquisition from Fructus Aurantii Immaturus or Fructus Aurantii.
4. purposes according to claim 1 and 2, wherein said Hesperidin and naringin obtain by chemosynthesis.
5. according to any one described purposes among the claim 1-3, wherein said medicine is an oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100426585A CN100569240C (en) | 2004-05-31 | 2004-05-31 | The pharmaceutical applications of Hesperidin and/or naringin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100426585A CN100569240C (en) | 2004-05-31 | 2004-05-31 | The pharmaceutical applications of Hesperidin and/or naringin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1704065A CN1704065A (en) | 2005-12-07 |
| CN100569240C true CN100569240C (en) | 2009-12-16 |
Family
ID=35575786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100426585A Expired - Lifetime CN100569240C (en) | 2004-05-31 | 2004-05-31 | The pharmaceutical applications of Hesperidin and/or naringin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100569240C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191239A (en) * | 2010-12-28 | 2013-07-10 | 江西青峰药业有限公司 | Fructus aurantii immaturus or fructus aurantii total-flavonoid extract obtained through ethanol reflux extraction and application thereof |
| CN105029334A (en) * | 2015-08-17 | 2015-11-11 | 范丹华 | Dangshen condiment |
| CN105294819A (en) * | 2015-10-20 | 2016-02-03 | 淄博夸克医药技术有限公司 | Novel limonin compound for treating breast cancer |
| CN105902556A (en) * | 2016-04-22 | 2016-08-31 | 江西中医药大学 | Combination medicine based on active components in Fructus Aurantii, and use thereof |
| CN114831303A (en) * | 2021-02-01 | 2022-08-02 | 健茂生物科技股份有限公司 | Composition with triglyceride reducing function and preparation method thereof |
-
2004
- 2004-05-31 CN CNB2004100426585A patent/CN100569240C/en not_active Expired - Lifetime
Non-Patent Citations (4)
| Title |
|---|
| 枳壳类药材的研究概况. 潘隽丽，杨翠平，苏薇薇.中药材，第26卷第10期. 2003 |
| 枳壳类药材的研究概况. 潘隽丽，杨翠平，苏薇薇.中药材，第26卷第10期. 2003 * |
| 陈皮及橙皮甙对小鼠胃排空、小肠推进功能的影响. 官福兰，王汝俊，王建华.中药药理与临床，第18卷第3期. 2002 |
| 陈皮及橙皮甙对小鼠胃排空、小肠推进功能的影响. 官福兰，王汝俊，王建华.中药药理与临床，第18卷第3期. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1704065A (en) | 2005-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101623366B (en) | Composition for curing gastrointestinal functional disorders, preparation method thereof and application thereof in preparing drugs for curing gastrointestinal functional disorders | |
| CN101015649A (en) | Dendrobium candidum polysaccharide extractive, medicine composition thereof and its preparation and use | |
| WO2001003715A1 (en) | Withania somnifera composition | |
| WO2011044751A1 (en) | Foliamangiferosides, preparation method and use thereof | |
| CN102178741A (en) | Guava leaf extract with function of reducing blood sugar as well as preparation method and application thereof | |
| WO2011063753A1 (en) | Traditional chinese medicine composition for treating oral ulcer and tumor, preparation method and use thereof | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN106065023A (en) | Hydrolysable tannin compounds, its medical composition and its use | |
| CN1836665B (en) | Pharmaceutical uses of hesperidin or its composition | |
| CN1733125B (en) | Pharmaceutical purpose of effective parts of immature Bitter orange or trifoliate-orange root-bark | |
| CN102342945B (en) | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament | |
| CN100569240C (en) | The pharmaceutical applications of Hesperidin and/or naringin | |
| CN103880856B (en) | Bisabolane sesquiterpene derivant and pharmaceutical composition thereof and its application in pharmacy | |
| CN101244105B (en) | Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses | |
| CN103880913B (en) | A kind of compound and application thereof with hepatoprotective effect | |
| CN103923156B (en) | There is saponin compound and the application thereof of hepatoprotective effect | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN101974011A (en) | New compound methyl brevicate with medical activity | |
| CN103864883B (en) | There is the triterpene saponin compound of liver protection function | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN100333746C (en) | Method for preparing Chinese medicine preparation for treating chronic conjestive heart-failure | |
| CN1857377A (en) | Preparation and application of total safflower flavone composition | |
| CN102078346B (en) | Chinese medicinal preparation for relieving heat, resisting inflammation and easing pain | |
| CN101974012A (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
| CN102093380A (en) | Cyclic icaritin aglycon as well as preparation method and application of cyclic icaritin aglycon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |